Update on Sermonix’s Elaine Phase 2 Clinical Programs
About The Event
The event will feature presentations from Key Opinion Leaders (KOL’s) Sarah Sammons, MD (Duke University) and Senthil Damodaran, MD, PhD (MD Anderson Cancer Center) who will discuss lasofoxifene, Sermonix’s investigational treatment for metastatic breast cancer with an acquired estrogen receptor 1 (ESR1) mutation.
Dr. Sammons will provide an overview of the Elaine-1 study, an open-label, randomized, multicenter study evaluating the activity of lasofoxifene versus fulvestrant (the current standard of care) in patients who have progressed following treatment with an aromatase inhibitor (Al), including in combination with a CDK 4/6 inhibitor.
Dr. Damodaran will then provide an analysis of efficacy and safety data from the Elaine-2 study, an open label multicenter study evaluating lasofoxifene in combination with Lilly’s CDK 4/6 inhibitor abemaciclib (VERZENIO®).
Following Dr. Damodaran and Dr. Sammons presentations, the Sermonix leadership team will provide a company overview and update.
A live question and answer session will follow.